Literature DB >> 17035092

Expression of human liver HSPGs on acute myeloid leukemia.

Preeyanat Vongchan1, Robert J Linhardt.   

Abstract

Heparan sulfate proteoglycans (HSPGs) play important biological roles in cell-matrix adhesion processes and are essential regulators of growth actions. The expression of the different HSPGs in itself is tightly regulated providing strict controls on the activities of the bound ligands. Human liver is a target for a number of pathogens, and HSPGs have been demonstrated in several cases to play a pivotal role in infectivity. Despite HSPGs important biological functions, little is known about its cell-specific distribution patterns. Human liver HSPG was isolated, and a specific monoclonal antibody (mAb) 1E4-1C2 was produced. Distribution of HSPG reactive to this mAb was studied in normal blood cells, hematopoietic cell lines and blood cells isolated from patients with various hematologic disorders using indirect immunofluorescence. There was no expression of molecules recognized by this mAb on lymphoid (Daudi, Jurkat, SupT-1) and monocytoid (U937) cell lines. Peripheral blood cells, normal bone marrow, together with leukocytes isolated from patients with acute lymphoblastic leukemia, chronic myelocytic leukemia, Hodgkin's disease or Non-Hodgkin's lymphoma, were also negative. In contrast, 1E4-1C2 showed significant positive results on human myeloid cell lines HL-60 and K562. Moreover, it is interesting that this mAb also recognized epitopes on leukocytes isolated from acute myeloblastic leukemia. These results suggest that malignancies of cells in myeloid lineage may cause expression of HSPGs that are detected by this specific mAb, making it a potential co-marker for the diagnosis of acute myeloid leukemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17035092      PMCID: PMC4142644          DOI: 10.1016/j.clim.2006.08.017

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  24 in total

Review 1.  Cell surface heparan sulfate proteoglycans: selective regulators of ligand-receptor encounters.

Authors:  P W Park; O Reizes; M Bernfield
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

2.  Structural characterization of human liver heparan sulfate.

Authors:  Preeyanat Vongchan; Mohamad Warda; Hidenao Toyoda; Toshihiko Toida; Rory M Marks; Robert J Linhardt
Journal:  Biochim Biophys Acta       Date:  2004-11-11

3.  New insights into the heparan sulfate proteoglycan-binding activity of apolipoprotein E.

Authors:  C P Libeu; S Lund-Katz; M C Phillips; S Wehrli; M J Hernáiz; I Capila; R J Linhardt; R L Raffaï; Y M Newhouse; F Zhou; K H Weisgraber
Journal:  J Biol Chem       Date:  2001-08-10       Impact factor: 5.157

4.  Mutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7.

Authors:  Stephen E Langabeer; Rosemary E Gale; Sara J Rollinson; Gareth J Morgan; David C Linch
Journal:  Genes Chromosomes Cancer       Date:  2002-05       Impact factor: 5.006

5.  Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate.

Authors:  Heidi Barth; Christiane Schafer; Mohammed I Adah; Fuming Zhang; Robert J Linhardt; Hidenao Toyoda; Akiko Kinoshita-Toyoda; Toshihiko Toida; Toin H Van Kuppevelt; Erik Depla; Fritz Von Weizsacker; Hubert E Blum; Thomas F Baumert
Journal:  J Biol Chem       Date:  2003-07-16       Impact factor: 5.157

6.  Proteoglycans mediate malaria sporozoite targeting to the liver.

Authors:  Gabriele Pradel; Shivani Garapaty; Ute Frevert
Journal:  Mol Microbiol       Date:  2002-08       Impact factor: 3.501

7.  Heparin inhibits dengue-2 virus infection of five human liver cell lines.

Authors:  Yin-Ling Lin; Huan-Yao Lei; Yee-Shin Lin; Trai-Ming Yeh; Shun-Hua Chen; Hsiao-Sheng Liu
Journal:  Antiviral Res       Date:  2002-10       Impact factor: 5.970

8.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).

Authors:  John C Byrd; Krzysztof Mrózek; Richard K Dodge; Andrew J Carroll; Colin G Edwards; Diane C Arthur; Mark J Pettenati; Shivanand R Patil; Kathleen W Rao; Michael S Watson; Prasad R K Koduru; Joseph O Moore; Richard M Stone; Robert J Mayer; Eric J Feldman; Frederick R Davey; Charles A Schiffer; Richard A Larson; Clara D Bloomfield
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

9.  Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data.

Authors:  Zahid Kaleem; Eric Crawford; M Hanif Pathan; Leah Jasper; Michael A Covinsky; Lawrence R Johnson; Glenda White
Journal:  Arch Pathol Lab Med       Date:  2003-01       Impact factor: 5.534

10.  Inhibition of apolipoprotein E-related neurotoxicity by glycosaminoglycans and their oligosaccharides.

Authors:  Hélène G Bazin; Marcos A Marques; Albert P Owens; Robert J Linhardt; Keith A Crutcher
Journal:  Biochemistry       Date:  2002-06-25       Impact factor: 3.162

View more
  5 in total

1.  A pH-sensitive heparin-binding sequence from Baculovirus gp64 protein is important for binding to mammalian cells but not to Sf9 insect cells.

Authors:  Chunxiao Wu; Shu Wang
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  HIV-1 entry in SupT1-R5, CEM-ss, and primary CD4+ T cells occurs at the plasma membrane and does not require endocytosis.

Authors:  Nikolas Herold; Maria Anders-Ößwein; Bärbel Glass; Manon Eckhardt; Barbara Müller; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2014-09-24       Impact factor: 5.103

3.  Transduction of Recombinant M3-p53-R12 Protein Enhances Human Leukemia Cell Apoptosis.

Authors:  Tsung Chi Lu; Guan-Hao Zhao; Yao Yun Chen; Chia-Ying Chien; Chi-Hung Huang; Kwang Hui Lin; Shen Liang Chen
Journal:  J Cancer       Date:  2016-06-28       Impact factor: 4.207

4.  Characterization of a new monoclonal anti-glypican-3 antibody specific to the hepatocellular carcinoma cell line, HepG2.

Authors:  Preeyanat Vongchan; Robert J Linhardt
Journal:  World J Hepatol       Date:  2017-03-08

5.  Interference with RUNX1/ETO leukemogenic function by cell-penetrating peptides targeting the NHR2 oligomerization domain.

Authors:  Yvonne Bartel; Manuel Grez; Christian Wichmann
Journal:  Biomed Res Int       Date:  2013-06-25       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.